Intellia Therapeutics, Inc.
NTLA · XNASCIK 1652130fmd_19AMT2RXJE4D6E1C2FN25YSBEWManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2015 to Sep 30, 2026, 47 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 16 | 26 | 30 | 43 | 58 | 33 | 52 | 36 | 58 | 68 |
| Cost of revenue | – | – | 0 | 0 | 0 | 0 | – | – | – | – |
| Gross profit | – | – | 30 | 43 | 58 | 33 | – | – | – | – |
| Realized investment gains (losses) | – | – | – | – | – | – | 0 | 0 | 0 | 0 |
| Research and development | 32 | 68 | 89 | 108 | 150 | 230 | 420 | 435 | 466 | 389 |
| Operating income | (32) | (70) | (91) | (106) | (137) | (268) | (458) | (515) | (534) | (441) |
| Interest and investment income | 1 | 2 | 6 | 7 | 2 | 1 | 9 | 50 | 48 | 29 |
| Other non-operating income (expense) | – | – | – | 7 | 2 | (0) | (16) | 34 | 15 | 28 |
| Income before taxes | (32) | (68) | – | – | – | – | – | – | – | – |
| Income tax expense | 0 | – | – | – | – | – | – | – | – | 0 |
| Net income from continuing operations | (32) | – | – | – | – | – | – | – | – | – |
| Net income | (32) | (68) | (85) | (474) | (134) | (268) | (474) | (481) | (519) | (413) |